A Systematic Review of the Effect of Delayed Appropriate Antibiotic Treatment on the Outcomes of Patients With Severe Bacterial Infections
- PMID: 32446623
- DOI: 10.1016/j.chest.2020.03.087
A Systematic Review of the Effect of Delayed Appropriate Antibiotic Treatment on the Outcomes of Patients With Severe Bacterial Infections
Abstract
Background: Patients with severe bacterial infections often experience delay in receiving appropriate treatment. Consolidated evidence of the impact of delayed appropriate treatment is needed to guide treatment and improve outcomes.
Research question: What is the impact of delayed appropriate antibacterial therapy on clinical outcomes in patients with severe bacterial infections?
Study design and methods: Literature searches of MEDLINE and Embase, conducted on July 24, 2018, identified studies published after 2007 reporting the impact of delayed appropriate therapy on clinical outcomes for hospitalized adult patients with bacterial infections. Where appropriate, results were pooled and analyzed with delayed therapy modeled three ways: delay vs no delay in receiving appropriate therapy; duration of delay; and inappropriate vs appropriate initial therapy. This article reports meta-analyses on the effect of delay and duration of delay.
Results: The eligibility criteria were met by 145 studies, of which 37 contributed data to analyses of effect of delay. Mortality was significantly lower in patients receiving appropriate therapy without delay compared with those experiencing delay (OR, 0.57; 95% CI, 0.45-0.72). Mortality was also lower in the no-delay group compared with the delay group in subgroups of studies reporting mortality at 20 to 30 days, during ICU stay, or in patients with bacteremia (OR, 0.57 [95% CI, 0.43-0.76]; OR, 0.47 [95% CI, 0.27-0.80]; and OR, 0.54 [95% CI, 0.40-0.75], respectively). No difference was found in time to appropriate therapy between those who died and those who survived (P = .09), but heterogeneity between studies was high.
Interpretation: Avoiding delayed appropriate therapy is essential to reduce mortality in patients with severe bacterial infections.
Clinical trial registration: PROSPERO; No.: CRD42018104669; URL: www.crd.york.ac.uk/prospero/.
Keywords: appropriate antibiotic therapy; mortality; severe infections; treatment delay.
Copyright © 2020. Published by Elsevier Inc.
Comment in
-
Mortality Benefit Inconclusive, Based on This Review.Chest. 2021 Apr;159(4):1676-1677. doi: 10.1016/j.chest.2020.08.2137. Epub 2021 Apr 6. Chest. 2021. PMID: 34021996 No abstract available.
-
Response.Chest. 2021 Apr;159(4):1677-1678. doi: 10.1016/j.chest.2020.11.029. Epub 2021 Apr 6. Chest. 2021. PMID: 34021997 No abstract available.
Similar articles
-
Systematic review of the impact of appropriate versus inappropriate initial antibiotic therapy on outcomes of patients with severe bacterial infections.Int J Antimicrob Agents. 2020 Dec;56(6):106184. doi: 10.1016/j.ijantimicag.2020.106184. Epub 2020 Oct 9. Int J Antimicrob Agents. 2020. PMID: 33045353
-
Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis.Health Technol Assess. 2015 Nov;19(96):v-xxv, 1-236. doi: 10.3310/hta19960. Health Technol Assess. 2015. PMID: 26569153 Free PMC article. Review.
-
Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections.Evid Based Child Health. 2013 Jul;8(4):1297-371. doi: 10.1002/ebch.1927. Evid Based Child Health. 2013. PMID: 23877944 Review.
-
Delayed antibiotics for symptoms and complications of respiratory infections.Cochrane Database Syst Rev. 2004 Oct 18;(4):CD004417. doi: 10.1002/14651858.CD004417.pub2. Cochrane Database Syst Rev. 2004. Update in: Cochrane Database Syst Rev. 2007 Jul 18;(3):CD004417. doi: 10.1002/14651858.CD004417.pub3. PMID: 15495108 Updated. Review.
-
Time Is of the Essence: The Impact of Delayed Antibiotic Therapy on Patient Outcomes in Hospital-Onset Enterococcal Bloodstream Infections.Clin Infect Dis. 2016 May 15;62(10):1242-1250. doi: 10.1093/cid/ciw110. Epub 2016 Mar 3. Clin Infect Dis. 2016. PMID: 26945013 Free PMC article.
Cited by
-
Outcomes of inadequate empiric therapy and timing of newer antibacterial therapy in hospitalized adults with culture-positive Enterobacterales and Pseudomonas aeruginosa: a multicenter analysis.BMC Infect Dis. 2024 Aug 9;24(1):810. doi: 10.1186/s12879-024-09700-7. BMC Infect Dis. 2024. PMID: 39123114 Free PMC article.
-
CTC-177, a novel drug-Fc conjugate, shows promise as an immunoprophylactic agent against multidrug-resistant Gram-negative bacterial infections.JAC Antimicrob Resist. 2024 Jul 26;6(4):dlae100. doi: 10.1093/jacamr/dlae100. eCollection 2024 Aug. JAC Antimicrob Resist. 2024. PMID: 39071163 Free PMC article.
-
New Agents Are Coming, and So Is the Resistance.Antibiotics (Basel). 2024 Jul 13;13(7):648. doi: 10.3390/antibiotics13070648. Antibiotics (Basel). 2024. PMID: 39061330 Free PMC article. Review.
-
Clinical and microbiological features of positive blood culture episodes caused by non-fermenting gram-negative bacilli other than Pseudomonas and Acinetobacter species (2020-2023).Infection. 2024 Jul 11. doi: 10.1007/s15010-024-02342-6. Online ahead of print. Infection. 2024. PMID: 38990473
-
Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model.Health Technol Assess. 2024 Jun;28(28):1-238. doi: 10.3310/YGWR4511. Health Technol Assess. 2024. PMID: 38938145 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous

